UMIN ID: C000000392
Registered date:31/12/2012
Treatment efficacy of pegintron alpha-2b and rivavirin for chronic hepatitis C patients with genotype 2 and high viral loads based on the dissapearance speed of serum HCV-RNA
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | chronic hepatitis C with genotype 2 and high viral loads |
| Date of first enrollment | 2006/01/01 |
| Target sample size | 150 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | pegintron alpha-2b/rivavirin for 12 weeks for SRVR group pegintron alpha-2b/rivavirin for 24 weeks for RVR group pegintron alpha-2b/rivavirin for 48 weeks for LVR group pegintron alpha-2b/rivavirin for 24 weeks for LVR group |
Outcome(s)
| Primary Outcome | virological responses and predictive factors associated each virological responses |
|---|---|
| Secondary Outcome | safety, dose reduction and discontinuation |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | chronic liver disease arising from other etiology allergy to interferon (IFN) during pregnancy severe complications-especially bone marrow, renal,cardiac, or respiratory dysfunction |
Related Information
| Primary Sponsor | Gunma Liver Study Group (GLSG) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Gunma Liver Study Group (GLSG) |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Ken Sato |
| Address | 3-39-22 Showa, Maebashi, Gunma, Japan Japan |
| Telephone | 0272-20-8127 |
| satoken@showa.gunma-u.ac.jp | |
| Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |
| scientific contact | |
| Name | Ken Sato |
| Address | 3-39-22 Showa, Maebashi, Gunma, Japan Japan |
| Telephone | 0272-20-8127 |
| satoken@gunma-u.ac.jp | |
| Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |